Chemical: Drug
bevacizumab

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.


1. FDA Label for bevacizumab

Full label available at DailyMed

Genes and/or phenotypes found in this label

  • Breast Neoplasms
    • Indications & usage section, Adverse reactions section
    • source: PHONT
  • Carcinoma, Renal Cell
    • Indications & usage section, Warnings section, Adverse reactions section
    • source: PHONT
  • Colorectal Neoplasms
    • Indications & usage section, Warnings section, Adverse reactions section
    • source: PHONT
  • Kidney Neoplasms
    • Warnings section
    • source: PHONT
  • Neoplasms
    • Indications & usage section, Warnings section, Adverse reactions section
    • source: PHONT
  • Neutropenia
    • Adverse reactions section
    • source: PHONT

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for bevacizumab

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA UGT1A1 *1 N/A N/A N/A
No VIP available No VIP available VA UGT1A1 *6 N/A N/A N/A
No VIP available No VIP available VA UGT1A1 *28 N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs1005510 NC_000011.10:g.57599749C>T, NC_000011.9:g.57367222C>T, NG_009625.1:g.7196C>T, NM_000062.2:c.52-130C>T, NM_001032295.1:c.52-130C>T, XM_005274204.1:c.52-115C>T, XM_005274205.1:c.52-130C>T, rs17661039, rs386509256, rs57537124
C > T
SNP
No VIP available CA VA
rs10490924 NC_000010.10:g.124214448G>T, NC_000010.11:g.122454932G>T, NG_011725.1:g.5270G>T, NM_001099667.1:c.205G>T, NP_001093137.1:p.Ala69Ser, XR_946382.1:n.1827+3563C>A, XR_946383.1:n.1827+3563C>A, XR_946384.1:n.1576+3563C>A, XR_946385.1:n.1917C>A, rs61632617
G > T
SNP
A69S
No VIP available No Clinical Annotations available VA
rs1049550 NC_000010.10:g.81926702G>A, NC_000010.11:g.80166946G>A, NM_001157.2:c.688C>T, NM_001278407.1:c.688C>T, NM_001278408.1:c.688C>T, NM_001278409.1:c.589C>T, NM_145868.1:c.688C>T, NM_145869.1:c.688C>T, NP_001148.1:p.Arg230Cys, NP_001265336.1:p.Arg230Cys, NP_001265337.1:p.Arg230Cys, NP_001265338.1:p.Arg197Cys, NP_665875.1:p.Arg230Cys, NP_665876.1:p.Arg230Cys, XM_005269741.1:c.988C>T, XM_005269741.3:c.988C>T, XM_005269742.1:c.688C>T, XM_006717813.1:c.688C>T, XM_006717814.2:c.688C>T, XM_011539735.1:c.688C>T, XM_011539736.1:c.688C>T, XP_005269798.1:p.Arg330Cys, XP_005269799.1:p.Arg230Cys, XP_006717876.1:p.Arg230Cys, XP_006717877.1:p.Arg230Cys, XP_011538037.1:p.Arg230Cys, XP_011538038.1:p.Arg230Cys, rs17676239, rs1802933, rs2070070, rs2228426, rs3189725, rs52830790
G > A
SNP
R230C
No VIP available No Clinical Annotations available VA
rs1051298 NC_000021.8:g.46934826G>A, NC_000021.9:g.45514912G>A, NG_011903.1:g.114721G>A, NG_028278.1:g.32560C>T, NM_001205206.1:c.*64C>T, NM_001205207.1:c.*746C>T, NM_194255.2:c.*746C>T, XM_005261163.1:c.*746C>T, XM_005261164.1:c.*746C>T, XM_005261164.2:c.*746C>T, XM_011529696.1:c.*746C>T, XM_011529697.1:c.*746C>T, XM_011529698.1:c.*746C>T, XM_011529699.1:c.*746C>T, XM_011529700.1:c.*746C>T, XM_011529701.1:c.*746C>T, XM_011529702.1:c.*746C>T, XM_011529703.1:c.*746C>T, XM_011529704.1:c.*746C>T, XM_011529705.1:c.*64C>T, XM_011529706.1:c.*746C>T, XM_011529707.1:c.1584+10905C>T, XM_011529708.1:c.*746C>T, XM_011529709.1:c.*746C>T, XM_011529710.1:c.*746C>T, rs3178001
G > A
SNP
No VIP available CA VA
rs1056515 NC_000001.10:g.163113260G>T, NC_000001.11:g.163143470G>T, NG_027731.2:g.183322C>A, NM_001195303.2:c.*3872C>A, NM_001254748.1:c.*3872C>A, NM_001254749.1:c.*3872C>A, NM_003617.3:c.*3872C>A, rs111183181, rs386514407, rs58775087, rs59069797
G > T
SNP
No VIP available CA VA
rs1061170 NC_000001.10:g.196659237C=, NC_000001.10:g.196659237C>T, NC_000001.11:g.196690107C=, NC_000001.11:g.196690107C>T, NG_007259.1:g.43097C=, NG_007259.1:g.43097C>T, NM_000186.3:c.1204C=, NM_000186.3:c.1204C>T, NM_001014975.2:c.1204C=, NM_001014975.2:c.1204C>T, NP_000177.2:p.His402=, NP_000177.2:p.His402Tyr, NP_001014975.1:p.His402=, NP_001014975.1:p.His402Tyr, XM_005245111.1:c.1204C=, XM_005245111.1:c.1204C>T, XM_005245112.1:c.1204C=, XM_005245112.1:c.1204C>T, XP_005245168.1:p.His402=, XP_005245168.1:p.His402Tyr, XP_005245169.1:p.His402=, XP_005245169.1:p.His402Tyr, rs60173482
C > T
SNP
H402Y
No VIP available No Clinical Annotations available VA
rs10801555 NC_000001.10:g.196660261A>G, NC_000001.11:g.196691131A>G, NG_007259.1:g.44121A>G, NM_000186.3:c.1336+892A>G, NM_001014975.2:c.1336+892A>G, XM_005245111.1:c.1336+892A>G, XM_005245112.1:c.1336+892A>G, rs60796007
A > G
SNP
No VIP available No Clinical Annotations available VA
rs10898563 NC_000011.10:g.86948171A>G, NC_000011.9:g.86659213A>G, NG_011752.1:g.12221T>C, NM_012193.3:c.*2971T>C, NR_120591.1:n.737-2185A>G, NR_120592.1:n.630-3045A>G, XM_005274341.1:c.*2971T>C, rs56551129, rs57097561
A > G
SNP
No VIP available CA VA
rs11200638 NC_000010.10:g.124220544G>A, NC_000010.11:g.122461028G>A, NG_011554.1:g.4504G>A, NM_002775.4:c.-625G>A, XR_946382.1:n.331C>T, XR_946383.1:n.331C>T, XR_946384.1:n.331C>T, XR_946385.1:n.331C>T
G > A
SNP
No VIP available No Clinical Annotations available VA
rs1127648 NC_000015.10:g.75674754A>G, NC_000015.9:g.75967095A>G, NM_001897.4:c.*796T>C, rs17591523, rs3183827, rs59364090
A > G
SNP
No VIP available No Clinical Annotations available VA
rs11545077 NC_000008.10:g.63951237C>T, NC_000008.11:g.63038678C>T, NG_028126.1:g.5374G>A, NM_003878.2:c.91G>A, NP_003869.1:p.Ala31Thr, XM_011517623.1:c.91G>A, XP_011515925.1:p.Ala31Thr, rs13270305, rs58961784
C > T
SNP
A31T
No VIP available No Clinical Annotations available VA
rs11580141 NC_000001.10:g.163135991G>A, NC_000001.11:g.163166201G>A, NG_027731.2:g.160591C>T, NM_001195303.2:c.-107-13485C>T, NM_001254748.1:c.-170+2057C>T, NM_001254749.1:c.155+2057C>T, NM_003617.3:c.155+2057C>T, NR_110699.1:n.258+3325G>A, XR_241139.1:n.261+3325G>A, rs111174851, rs59021939
G > A
SNP
No VIP available No Clinical Annotations available VA
rs11997869 NC_000008.10:g.6638464C>G, NC_000008.11:g.6780943C>G
C > A
C > G
SNP
No VIP available No Clinical Annotations available VA
rs12712973 NC_000002.11:g.46556633A>C, NC_000002.12:g.46329494A>C, NG_016000.1:g.37093A>C, NM_001430.4:c.27-17379A>C, XM_011532698.1:c.65+3618A>C, XR_940055.1:n.2355+6290T>G, rs59714548
A > C
SNP
No VIP available No Clinical Annotations available VA
rs12877323 NC_000013.10:g.28879921T>G, NC_000013.11:g.28305784T>G, NG_012003.1:g.194345A>C, NM_002019.4:c.3815+894A>C
T > G
SNP
No VIP available No Clinical Annotations available VA
rs1374749 NC_000002.11:g.46596433G>A, NC_000002.12:g.46369294G>A, NG_016000.1:g.76893G>A, NM_001430.4:c.780-533G>A, XM_011532698.1:c.819-533G>A, rs58613482
G > A
SNP
No VIP available No Clinical Annotations available VA
rs1410996 NC_000001.10:g.196696933G=, NC_000001.10:g.196696933G>A, NC_000001.11:g.196727803G=, NC_000001.11:g.196727803G>A, NG_007259.1:g.80793G=, NG_007259.1:g.80793G>A, NM_000186.3:c.2237-543G=, NM_000186.3:c.2237-543G>A, rs3766406, rs386530952, rs58851244
G > A
SNP
No VIP available No Clinical Annotations available VA
rs1570360 NC_000006.11:g.43737830A>G, NC_000006.12:g.43770093A>G, NG_008732.1:g.4878A>G, NM_001025366.2:c.-614A>G, NM_001025367.2:c.-614A>G, NM_001025368.2:c.-614A>G, NM_001025369.2:c.-614A>G, NM_001025370.2:c.-614A>G, NM_001033756.2:c.-614A>G, NM_001171622.1:c.-614A>G, NM_001171623.1:c.-1154A>G, NM_001171624.1:c.-1154A>G, NM_001171625.1:c.-1154A>G, NM_001171626.1:c.-1154A>G, NM_001171627.1:c.-1154A>G, NM_001171628.1:c.-1154A>G, NM_001171629.1:c.-1154A>G, NM_001171630.1:c.-1154A>G, NM_001204384.1:c.-1154A>G, NM_001204385.1:c.-614A>G, NM_001287044.1:c.-2027A>G, NM_001317010.1:c.-1154A>G, NM_003376.5:c.-614A>G, XM_005249363.1:c.-2027A>G, rs36208386, rs58036053
A > G
SNP
No VIP available No Clinical Annotations available VA
rs1617640 NC_000007.13:g.100317298C>A, NC_000007.14:g.100719675C>A, NG_021471.1:g.3876C>A, NM_000799.2:c.-1306C>A, XM_005250190.1:c.-1306C>A, rs10304599, rs10342152, rs57979509
C > A
SNP
No VIP available No Clinical Annotations available VA
rs1629140 NC_000014.8:g.34413826A>G, NC_000014.9:g.33944620A>G, NM_001308103.1:c.75+6058T>C, NM_022073.3:c.357+5776T>C, XM_006720015.2:c.75+6058T>C, rs17506218, rs60386310
A > G
SNP
No VIP available CA VA
rs1801131 NC_000001.10:g.11854476T>G, NC_000001.11:g.11794419T>G, NG_013351.1:g.16685A>C, NM_005957.4:c.1286A>C, NP_005948.3:p.Glu429Ala, XM_005263458.1:c.1409A>C, XM_005263458.2:c.1409A>C, XM_005263459.1:c.1355A>C, XM_005263460.1:c.1286A>C, XM_005263460.3:c.1286A>C, XM_005263461.1:c.1286A>C, XM_005263461.3:c.1286A>C, XM_005263462.1:c.1286A>C, XM_005263462.3:c.1286A>C, XM_005263463.1:c.1040A>C, XM_005263463.2:c.1040A>C, XM_011541495.1:c.1406A>C, XM_011541496.1:c.1409A>C, XP_005263515.1:p.Glu470Ala, XP_005263516.1:p.Glu452Ala, XP_005263517.1:p.Glu429Ala, XP_005263518.1:p.Glu429Ala, XP_005263519.1:p.Glu429Ala, XP_005263520.1:p.Glu347Ala, XP_011539797.1:p.Glu469Ala, XP_011539798.1:p.Glu470Ala, rs17367365, rs17857426, rs4134712
T > G
SNP
E429A
No VIP available CA VA
rs1979277 NC_000017.10:g.18232096G>A, NC_000017.11:g.18328782G>A, NG_017111.1:g.39761C>T, NM_001281786.1:c.1006C>T, NM_004169.4:c.1420C>T, NM_148918.2:c.1303C>T, NP_001268715.1:p.Leu336Phe, NP_004160.3:p.Leu474Phe, NP_683718.1:p.Leu435Phe, XM_005256767.1:c.1420C>T, XM_005256767.2:c.1420C>T, XM_005256768.1:c.1006C>T, XM_011523992.1:c.1180C>T, XP_005256824.1:p.Leu474Phe, XP_005256825.1:p.Leu336Phe, XP_011522294.1:p.Leu394Phe, rs17850285, rs2230025, rs3183766, rs57933897
G > A
SNP
L336F
No VIP available CA VA
rs2010963 NC_000006.11:g.43738350C>G, NC_000006.12:g.43770613C>G, NG_008732.1:g.5398C>G, NM_001025366.2:c.-94C>G, NM_001025367.2:c.-94C>G, NM_001025368.2:c.-94C>G, NM_001025369.2:c.-94C>G, NM_001025370.2:c.-94C>G, NM_001033756.2:c.-94C>G, NM_001171622.1:c.-94C>G, NM_001171623.1:c.-634C>G, NM_001171624.1:c.-634C>G, NM_001171625.1:c.-634C>G, NM_001171626.1:c.-634C>G, NM_001171627.1:c.-634C>G, NM_001171628.1:c.-634C>G, NM_001171629.1:c.-634C>G, NM_001171630.1:c.-634C>G, NM_001204384.1:c.-634C>G, NM_001204385.1:c.-94C>G, NM_001287044.1:c.-1507C>G, NM_001317010.1:c.-634C>G, NM_003376.5:c.-94C>G, XM_005249363.1:c.-1507C>G
C > G
SNP
No VIP available No Clinical Annotations available VA
rs2073016 NC_000006.11:g.41020922T>C, NC_000006.12:g.41053183T>C, NM_006789.3:c.-165T>C
T > C
SNP
No VIP available No Clinical Annotations available VA
rs2146323 NC_000006.11:g.43745095C>A, NC_000006.12:g.43777358C>A, NG_008732.1:g.12143C>A, NM_001025366.2:c.659-111C>A, NM_001025367.2:c.659-111C>A, NM_001025368.2:c.659-111C>A, NM_001025369.2:c.659-111C>A, NM_001025370.2:c.659-111C>A, NM_001033756.2:c.659-111C>A, NM_001171622.1:c.659-111C>A, NM_001171623.1:c.119-111C>A, NM_001171624.1:c.119-111C>A, NM_001171625.1:c.119-111C>A, NM_001171626.1:c.119-111C>A, NM_001171627.1:c.119-111C>A, NM_001171628.1:c.119-111C>A, NM_001171629.1:c.119-111C>A, NM_001171630.1:c.119-111C>A, NM_001204384.1:c.119-111C>A, NM_001204385.1:c.659-111C>A, NM_001287044.1:c.35-111C>A, NM_001317010.1:c.119-111C>A, NM_003376.5:c.659-111C>A, XM_005249363.1:c.35-111C>A
C > A
SNP
No VIP available No Clinical Annotations available VA
rs2230054 NC_000002.11:g.219000310C>T, NC_000002.12:g.218135587C>T, NM_001168298.1:c.786C>T, NM_001557.3:c.786C>T, NP_001161770.1:p.Leu262=, NP_001548.1:p.Leu262=, XM_005246529.1:c.786C>T, XM_005246530.1:c.786C>T, XM_005246530.2:c.786C>T, XM_005246531.1:c.786C>T, XP_005246586.1:p.Leu262=, XP_005246587.1:p.Leu262=, XP_005246588.1:p.Leu262=, rs17844700, rs2234672, rs3883989, rs57849916
C > T
SNP
L262L
No VIP available No Clinical Annotations available VA
rs2230199 NC_000019.10:g.6718376G>C, NC_000019.9:g.6718387G>C, NG_009557.1:g.7276C>G, NM_000064.2:c.304C>G, NM_000064.3:c.304C>G, NP_000055.2:p.Arg102Gly, rs11569409
G > C
SNP
R102G
No VIP available No Clinical Annotations available VA
rs2230205 NC_000019.10:g.6709693C>T, NC_000019.9:g.6709704C>T, NG_009557.1:g.15959G>A, NM_000064.2:c.1836G>A, NM_000064.3:c.1836G>A, NP_000055.2:p.Thr612=, rs17718234, rs3745560, rs41313147, rs57515675
C > T
SNP
T612T
No VIP available No Clinical Annotations available VA
rs2250656 NC_000019.10:g.6718523T>C, NC_000019.9:g.6718534T>C, NG_009557.1:g.7129A>G, NM_000064.2:c.268-111A>G, NM_000064.3:c.268-111A>G, rs386562560, rs57061109
T > C
SNP
No VIP available No Clinical Annotations available VA
rs2286455 NC_000004.11:g.16020162C>T, NC_000004.12:g.16018539C>T, NG_011696.1:g.70462G>A, NM_001145847.1:c.759G>A, NM_001145848.1:c.759G>A, NM_001145849.1:c.786G>A, NM_001145850.1:c.786G>A, NM_001145851.1:c.759G>A, NM_001145852.1:c.759G>A, NM_006017.2:c.786G>A, NP_001139319.1:p.Ala253=, NP_001139320.1:p.Ala253=, NP_001139321.1:p.Ala262=, NP_001139322.1:p.Ala262=, NP_001139323.1:p.Ala253=, NP_001139324.1:p.Ala253=, NP_006008.1:p.Ala262=, XM_005248194.1:c.786G>A, XM_005248195.1:c.759G>A, XM_005248195.3:c.759G>A, XM_005248196.1:c.759G>A, XM_005248196.3:c.759G>A, XM_006713974.2:c.552G>A, XM_011513890.1:c.786G>A, XM_011513891.1:c.786G>A, XM_011513892.1:c.786G>A, XM_011513893.1:c.786G>A, XM_011513894.1:c.786G>A, XM_011513895.1:c.786G>A, XM_011513896.1:c.786G>A, XM_011513897.1:c.786G>A, XM_011513898.1:c.786G>A, XM_011513899.1:c.759G>A, XM_011513900.1:c.786G>A, XM_011513901.1:c.786G>A, XM_011513902.1:c.786G>A, XM_011513903.1:c.579G>A, XM_011513904.1:c.513G>A, XP_005248251.1:p.Ala262=, XP_005248252.1:p.Ala253=, XP_005248253.1:p.Ala253=, XP_006714037.1:p.Ala184=, XP_011512192.1:p.Ala262=, XP_011512193.1:p.Ala262=, XP_011512194.1:p.Ala262=, XP_011512195.1:p.Ala262=, XP_011512196.1:p.Ala262=, XP_011512197.1:p.Ala262=, XP_011512198.1:p.Ala262=, XP_011512199.1:p.Ala262=, XP_011512200.1:p.Ala262=, XP_011512201.1:p.Ala253=, XP_011512202.1:p.Ala262=, XP_011512203.1:p.Ala262=, XP_011512204.1:p.Ala262=, XP_011512205.1:p.Ala193=, XP_011512206.1:p.Ala171=, rs56605149, rs60672150
C > T
SNP
A253A
No VIP available No Clinical Annotations available VA
rs2302273 NC_000005.10:g.150155692G>A, NC_000005.9:g.149535255G>A, NG_023367.1:g.5168C>T, NM_002609.3:c.-302C>T, XM_005268464.1:c.-448C>T, XM_005268464.2:c.-448C>T, XM_011537659.1:c.-769C>T, rs56934659
G > A
SNP
No VIP available No Clinical Annotations available VA
rs2511989 NC_000011.10:g.57610852C>T, NC_000011.9:g.57378325C>T, NG_009625.1:g.18299C>T, NM_000062.2:c.1030-865C>T, NM_001032295.1:c.1030-865C>T, XM_005274204.1:c.1045-865C>T, XM_005274205.1:c.1030-865C>T, rs56451052, rs57180821
C > T
SNP
No VIP available No Clinical Annotations available VA
rs2661280 NC_000001.10:g.163113375G>C, NC_000001.11:g.163143585G>C, NG_027731.2:g.183207C>G, NM_001195303.2:c.*3757C>G, NM_001254748.1:c.*3757C>G, NM_001254749.1:c.*3757C>G, NM_003617.3:c.*3757C>G, rs17361582, rs56558782, rs57479307, rs60251204
G > C
SNP
No VIP available No Clinical Annotations available VA
rs2912024 NC_000008.10:g.6638899C>T, NC_000008.11:g.6781378C>T, rs56641910, rs57353971
C > T
SNP
No VIP available No Clinical Annotations available VA
rs2928607 NC_000008.10:g.6638710C>G, NC_000008.11:g.6781189C>G
C > G
SNP
No VIP available No Clinical Annotations available VA
rs2928608 NC_000008.10:g.6639024T>C, NC_000008.11:g.6781503T>C, rs58017964
T > C
SNP
No VIP available No Clinical Annotations available VA
rs2928609 NC_000008.10:g.6639118T>C, NC_000008.11:g.6781597T>C, rs56794760
T > C
SNP
No VIP available No Clinical Annotations available VA
rs2936519 NC_000008.10:g.6639240G>A, NC_000008.11:g.6781719G>A, rs59917631
G > A
SNP
No VIP available No Clinical Annotations available VA
rs2978926 NC_000008.10:g.6639425A>G, NC_000008.11:g.6781904A>G, rs56514514, rs57794753, rs58364937
A > G
SNP
No VIP available No Clinical Annotations available VA
rs2978931 NC_000008.10:g.6638081C>A, NC_000008.11:g.6780560C>A, rs386578178, rs59726576
C > A
SNP
No VIP available CA VA
rs3025000 NC_000006.11:g.43746169C>T, NC_000006.12:g.43778432C>T, NG_008732.1:g.13217C>T, NM_001025366.2:c.856-28C>T, NM_001025367.2:c.856-28C>T, NM_001025368.2:c.856-28C>T, NM_001025369.2:c.856-28C>T, NM_001025370.2:c.856-28C>T, NM_001033756.2:c.856-28C>T, NM_001171622.1:c.856-28C>T, NM_001171623.1:c.316-28C>T, NM_001171624.1:c.316-28C>T, NM_001171625.1:c.316-28C>T, NM_001171626.1:c.316-28C>T, NM_001171627.1:c.316-28C>T, NM_001171628.1:c.316-28C>T, NM_001171629.1:c.316-28C>T, NM_001171630.1:c.316-28C>T, NM_001204384.1:c.316-28C>T, NM_001204385.1:c.856-28C>T, NM_001287044.1:c.232-28C>T, NM_001317010.1:c.316-28C>T, NM_003376.5:c.856-28C>T, XM_005249363.1:c.232-28C>T, rs3730318, rs60421248
C > T
SNP
No VIP available No Clinical Annotations available VA
rs3025030 NC_000006.11:g.43750587G>C, NC_000006.12:g.43782850G>C, NG_008732.1:g.17635G>C, NM_001025366.2:c.1217+763G>C, NM_001025367.2:c.1148+763G>C, NM_001025368.2:c.1094+763G>C, NM_001025369.2:c.1059+798G>C, NM_001025370.2:c.963-1691G>C, NM_001033756.2:c.1094+763G>C, NM_001171622.1:c.933-1691G>C, NM_001171623.1:c.677+763G>C, NM_001171624.1:c.626+763G>C, NM_001171625.1:c.608+763G>C, NM_001171626.1:c.554+763G>C, NM_001171627.1:c.519+798G>C, NM_001171628.1:c.423-1691G>C, NM_001171629.1:c.554+763G>C, NM_001171630.1:c.393-1691G>C, NM_001204384.1:c.495-1691G>C, NM_001204385.1:c.1035-1691G>C, NM_001287044.1:c.470+763G>C, NM_001317010.1:c.554+763G>C, NM_003376.5:c.1166+763G>C, XM_005249363.1:c.470+763G>C, rs16896816, rs3799959, rs61356923
G > C
SNP
No VIP available No Clinical Annotations available VA
rs3025033 NC_000006.11:g.43751075A>G, NC_000006.12:g.43783338A>G, NG_008732.1:g.18123A>G, NM_001025366.2:c.1218-1203A>G, NM_001025367.2:c.1149-1203A>G, NM_001025368.2:c.1095-1203A>G, NM_001025369.2:c.1060-1203A>G, NM_001025370.2:c.963-1203A>G, NM_001033756.2:c.1094+1251A>G, NM_001171622.1:c.933-1203A>G, NM_001171623.1:c.678-1203A>G, NM_001171624.1:c.627-1203A>G, NM_001171625.1:c.609-1203A>G, NM_001171626.1:c.555-1203A>G, NM_001171627.1:c.520-1203A>G, NM_001171628.1:c.423-1203A>G, NM_001171629.1:c.554+1251A>G, NM_001171630.1:c.393-1203A>G, NM_001204384.1:c.495-1203A>G, NM_001204385.1:c.1035-1203A>G, NM_001287044.1:c.471-1203A>G, NM_001317010.1:c.555-1203A>G, NM_003376.5:c.1167-1203A>G, XM_005249363.1:c.471-1203A>G, rs3778502, rs59547322
A > G
SNP
No VIP available CA VA
rs3025039 NC_000006.11:g.43752536C>T, NC_000006.12:g.43784799C>T, NG_008732.1:g.19584C>T, NM_001025366.2:c.*237C>T, NM_001025367.2:c.*237C>T, NM_001025368.2:c.*237C>T, NM_001025369.2:c.*253C>T, NM_001025370.2:c.*237C>T, NM_001033756.2:c.*171C>T, NM_001171622.1:c.*237C>T, NM_001171623.1:c.*237C>T, NM_001171624.1:c.*237C>T, NM_001171625.1:c.*237C>T, NM_001171626.1:c.*237C>T, NM_001171627.1:c.*253C>T, NM_001171628.1:c.*237C>T, NM_001171629.1:c.*171C>T, NM_001171630.1:c.*237C>T, NM_001204384.1:c.*237C>T, NM_001204385.1:c.*237C>T, NM_001287044.1:c.*237C>T, NM_001317010.1:c.*171C>T, NM_003376.5:c.*237C>T, XM_005249363.1:c.*237C>T, rs11575898
C > T
SNP
No VIP available No Clinical Annotations available VA
rs3130 NC_000004.11:g.15969938T>C, NC_000004.12:g.15968315T>C, NG_011696.1:g.120686A>G, NM_001145847.1:c.*1078A>G, NM_001145848.1:c.*1078A>G, NM_001145849.1:c.*1078A>G, NM_001145850.1:c.*1078A>G, NM_001145851.1:c.*1078A>G, NM_001145852.1:c.*1078A>G, NM_006017.2:c.*1078A>G, XM_005248194.1:c.*1078A>G, XM_005248195.1:c.*1078A>G, XM_005248195.3:c.*1078A>G, XM_005248196.1:c.*1078A>G, XM_005248196.3:c.*1078A>G, XM_006713974.2:c.*1078A>G, XM_011513890.1:c.*1078A>G, XM_011513891.1:c.*1078A>G, XM_011513892.1:c.*1078A>G, XM_011513893.1:c.*1078A>G, XM_011513894.1:c.*1078A>G, XM_011513895.1:c.*1078A>G, XM_011513896.1:c.*1078A>G, XM_011513897.1:c.*1078A>G, XM_011513900.1:c.*1078A>G, XM_011513901.1:c.*1078A>G, XM_011513902.1:c.*1078A>G, XM_011513903.1:c.*1078A>G, XM_011513904.1:c.*1078A>G, rs11552440, rs17477709, rs3194369, rs56565902, rs60023481, rs60646405, rs7752
T > C
SNP
No VIP available No Clinical Annotations available VA
rs323719 NC_000001.10:g.43270928G>A, NC_000001.11:g.42805257G>A
G > A
SNP
No VIP available No Clinical Annotations available VA
rs323720 NC_000001.10:g.43271033T>C, NC_000001.11:g.42805362T>C, rs57992297
T > C
SNP
No VIP available No Clinical Annotations available VA
rs329007 NC_000018.10:g.9522608G>A, NC_000018.9:g.9522606G>A, NM_006788.3:c.1053+99G>A, XM_005258080.1:c.1053+99G>A, rs59437962
G > A
SNP
No VIP available No Clinical Annotations available VA
rs3768728 NC_000002.11:g.46590791T>C, NC_000002.12:g.46363652T>C, NG_016000.1:g.71251T>C, NM_001430.4:c.779+2562T>C, XM_011532698.1:c.818+2562T>C, rs60273833
T > C
SNP
No VIP available CA VA
rs3780126 NC_000008.10:g.63949912G>A, NC_000008.11:g.63037353G>A, NG_028126.1:g.6699C>T, NM_003878.2:c.109+1307C>T, XM_011517623.1:c.109+1307C>T, rs58946583
G > A
SNP
No VIP available No Clinical Annotations available VA
rs3804454 NC_000006.11:g.36006998T>G, NC_000006.12:g.36039221T>G, NM_001315.2:c.116+10948T>G, NM_139012.2:c.116+10948T>G, NM_139013.2:c.116+10948T>G, NM_139014.2:c.116+10948T>G, XM_006714998.2:c.-116+10061T>G, XM_011514310.1:c.41+10722T>G, XM_011514311.1:c.116+10948T>G, XR_241882.1:n.639+10948T>G, XR_926065.1:n.639+10948T>G, XR_926067.1:n.639+10948T>G, XR_926068.1:n.639+10948T>G, rs59969248
T > G
SNP
No VIP available CA VA
rs4073 NC_000004.11:g.74606024A>T, NC_000004.12:g.73740307A>T, NG_029889.1:g.4802A>T, NM_000584.3:c.-352A>T
A > T
SNP
No VIP available No Clinical Annotations available VA
rs4377367 NC_000002.11:g.131724905C>T, NC_000002.12:g.130967332C>T, NM_015320.3:c.427+20697C>T, NM_032995.2:c.427+20697C>T, XM_005263681.1:c.3985+20697C>T, XM_005263682.1:c.3874+20697C>T, XM_005263683.1:c.3985+20697C>T, XM_005263687.1:c.58+3083C>T, XM_005263687.2:c.58+3083C>T, XM_011511274.1:c.3985+20697C>T, XM_011511275.1:c.3949+20697C>T, XM_011511276.1:c.-55+20697C>T, XR_244821.1:n.4023+20697C>T, rs58214874
C > T
SNP
No VIP available No Clinical Annotations available VA
rs4953344 NC_000002.11:g.46552458T>C, NC_000002.12:g.46325319T>C, NG_016000.1:g.32918T>C, NM_001430.4:c.27-21554T>C, XM_011532698.1:c.-493T>C, XR_940055.1:n.2355+10465A>G, rs17746007, rs56802594
T > C
SNP
No VIP available No Clinical Annotations available VA
rs671976 NC_000011.10:g.64278557G>A, NC_000011.9:g.64046029G>A, NM_004322.3:c.187+5625C>T, NM_032989.2:c.187+5625C>T, XM_011545168.1:c.3+7896G>A, XM_011545170.1:c.3+7896G>A, XM_011545171.1:c.3+7896G>A, XM_011545172.1:c.3+7896G>A, rs58298578
G > A
SNP
No VIP available No Clinical Annotations available VA
rs6726454 NC_000002.11:g.46561202A>G, NC_000002.12:g.46334063A>G, NG_016000.1:g.41662A>G, NM_001430.4:c.27-12810A>G, XM_011532698.1:c.65+8187A>G, XR_940055.1:n.2355+1721T>C, rs59690653
A > G
SNP
No VIP available CA VA
rs699947 NC_000006.11:g.43736389A>C, NC_000006.12:g.43768652A>C, NG_008732.1:g.3437A>C, NM_001025366.2:c.-2055A>C, NM_001025367.2:c.-2055A>C, NM_001025368.2:c.-2055A>C, NM_001025369.2:c.-2055A>C, NM_001025370.2:c.-2055A>C, NM_001033756.2:c.-2055A>C, NM_001171622.1:c.-2055A>C, NM_001171623.1:c.-2595A>C, NM_001171624.1:c.-2595A>C, NM_001171625.1:c.-2595A>C, NM_001171626.1:c.-2595A>C, NM_001171627.1:c.-2595A>C, NM_001171628.1:c.-2595A>C, NM_001171629.1:c.-2595A>C, NM_001171630.1:c.-2595A>C, NM_001204384.1:c.-2595A>C, NM_001204385.1:c.-2055A>C, NM_001317010.1:c.-2595A>C, NM_003376.5:c.-2055A>C, rs1310065, rs36208051, rs61399354
A > C
SNP
No VIP available No Clinical Annotations available VA
rs7589621 NC_000002.11:g.46582382G>A, NC_000002.12:g.46355243G>A, NG_016000.1:g.62842G>A, NM_001430.4:c.218-908G>A, XM_011532698.1:c.257-908G>A, rs61027574
G > A
SNP
No VIP available No Clinical Annotations available VA
rs7995976 NC_000013.10:g.28941060A>C, NC_000013.11:g.28366923A>C, NG_012003.1:g.133206T>G, NM_002019.4:c.2117-9238T>G, rs61179897, rs9513092
A > C
SNP
No VIP available CA VA
rs800292 NC_000001.10:g.196642233G>A, NC_000001.11:g.196673103G>A, NG_007259.1:g.26093G>A, NM_000186.3:c.184G>A, NM_001014975.2:c.184G>A, NP_000177.2:p.Val62Ile, NP_001014975.1:p.Val62Ile, XM_005245111.1:c.184G>A, XM_005245112.1:c.184G>A, XP_005245168.1:p.Val62Ile, XP_005245169.1:p.Val62Ile, rs117675270, rs1292481, rs1738751, rs386614680, rs52795952, rs56426712, rs60919873
G > A
SNP
V62I
No VIP available No Clinical Annotations available VA
rs833058 NC_000006.11:g.43731854C>T, NC_000006.12:g.43764117C>T, rs58522910
C > T
SNP
No VIP available No Clinical Annotations available VA
rs833061 NC_000006.11:g.43737486C>T, NC_000006.12:g.43769749C>T, NG_008732.1:g.4534C>T, NM_001025366.2:c.-958C>T, NM_001025367.2:c.-958C>T, NM_001025368.2:c.-958C>T, NM_001025369.2:c.-958C>T, NM_001025370.2:c.-958C>T, NM_001033756.2:c.-958C>T, NM_001171622.1:c.-958C>T, NM_001171623.1:c.-1498C>T, NM_001171624.1:c.-1498C>T, NM_001171625.1:c.-1498C>T, NM_001171626.1:c.-1498C>T, NM_001171627.1:c.-1498C>T, NM_001171628.1:c.-1498C>T, NM_001171629.1:c.-1498C>T, NM_001171630.1:c.-1498C>T, NM_001204384.1:c.-1498C>T, NM_001204385.1:c.-958C>T, NM_001317010.1:c.-1498C>T, NM_003376.5:c.-958C>T, rs36208046, rs60746584
C > T
SNP
No VIP available No Clinical Annotations available VA
rs833069 NC_000006.11:g.43742579T>C, NC_000006.12:g.43774842T>C, NG_008732.1:g.9627T>C, NM_001025366.2:c.658+450T>C, NM_001025367.2:c.658+450T>C, NM_001025368.2:c.658+450T>C, NM_001025369.2:c.658+450T>C, NM_001025370.2:c.658+450T>C, NM_001033756.2:c.658+450T>C, NM_001171622.1:c.658+450T>C, NM_001171623.1:c.118+450T>C, NM_001171624.1:c.118+450T>C, NM_001171625.1:c.118+450T>C, NM_001171626.1:c.118+450T>C, NM_001171627.1:c.118+450T>C, NM_001171628.1:c.118+450T>C, NM_001171629.1:c.118+450T>C, NM_001171630.1:c.118+450T>C, NM_001204384.1:c.118+450T>C, NM_001204385.1:c.658+450T>C, NM_001287044.1:c.34+450T>C, NM_001317010.1:c.118+450T>C, NM_003376.5:c.658+450T>C, XM_005249363.1:c.34+450T>C, rs1612658, rs3778495, rs386616780, rs61226611
T > C
SNP
No VIP available CA VA
rs885036 NC_000002.11:g.99304794A>G, NC_000002.12:g.98688331A>G, NM_012214.2:c.95-9860T>C, XM_005263866.1:c.95-9860T>C, XM_005263867.1:c.-637-9860T>C, rs17448475, rs60397503
A > G
SNP
No VIP available No Clinical Annotations available VA
rs9679290 NC_000002.11:g.46557644G>C, NC_000002.12:g.46330505G>C, NG_016000.1:g.38104G>C, NM_001430.4:c.27-16368G>C, XM_011532698.1:c.65+4629G>C, XR_940055.1:n.2355+5279C>G, rs17802721, rs56551236, rs60991579
G > C
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • Avastin
  • R-435
  • antiVEGF
  • bevacizumab
Trade Names
  • Avastin (Genentech Inc)
Brand Mixture Names

PharmGKB Accession Id

PA130232992

Type(s):

Drug

Description

A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.

Source: Drug Bank

Indication

As part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. This prevents blood vessel proliferation and tumour metastasis.

Source: Drug Bank

Pharmacology

Bevacizumab prevents or reduces the formation of blood vessels (angiogenesis) thereby preventing or reducing metatstatic disease progressing. Bevacizumab binds VEGF and prevents vascular endothelial growth and endothelial cell proliferation.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Most likely removed by opsonization via the reticuloendothelial system when bound to endothelial cells, or by human antimurine antibody production

Source: Drug Bank

Chemical Properties

Canonical SMILES

Not Available

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. VEGF Signaling Pathway
    Model endothelial cell displaying genes of the VEGF signalling pathway and the sites at which bevacizumab, sorafenib, sunitinib, brivanib and cilengitide are known to act.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
C1QA (source: Drug Bank)
C1QB (source: Drug Bank)
C1QC (source: Drug Bank)
C1R (source: Drug Bank)
FCGR1A (source: Drug Bank)
FCGR2A (source: Drug Bank)
FCGR2B (source: Drug Bank)
FCGR2C (source: Drug Bank)
FCGR3A (source: Drug Bank)
FCGR3B (source: Drug Bank)
VEGFA (source: Drug Bank)
No related drugs are available.

Curated Information ?

Publications related to bevacizumab: 52

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. International journal of cancer. Journal international du cancer. 2015. Hein Alexander, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
BRAF in metastatic colorectal cancer: the future starts now. Pharmacogenomics. 2015. Orlandi Armando. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Serum C-telopeptide collagen crosslinks and plasma soluble VEGFR2 as pharmacodynamic biomarkers in a trial of sequentially administered sunitinib and cilengitide. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015. O'Donnell Peter H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. Cancer chemotherapy and pharmacology. 2015. Panoilia Eirini, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. The pharmacogenomics journal. 2015. Volz N B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic Effect of Complement Factor H Gene Polymorphism in Response to the Initial Intravitreal Injection of Bevacizumab for Wet Age-Related Macular Degeneration. Ophthalmic research. 2015. Medina Flavio Mac Cord, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis. PloS one. 2015. Wang Lei, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer. PloS one. 2015. Pander Jan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis. Scientific reports. 2015. Chen Guohai, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer. 2014. Patel Jai N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic research in partnership with American Indian and Alaska Native communities. Pharmacogenomics. 2014. Woodahl Erica L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of solute carrier transporters in pancreatic cancer: a review. Pharmacogenomics. 2014. Lemstrová Radmila, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014. Salgia Ravi, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration. Retina (Philadelphia, Pa.). 2014. Park Un Chul, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. Journal of clinical pharmacology. 2014. Suenaga Mitsukuni, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia. Ophthalmology. 2014. Miyake Masahiro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study. Ophthalmology. 2013. Lotery Andrew J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
VEGF pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a 2013 update. Pharmacogenomics. 2013. Eng Lawson, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Interleukin 8 promoter polymorphism predicts the initial response to bevacizumab treatment for exudative age-related macular degeneration. Retina (Philadelphia, Pa.). 2013. Hautamäki Asta, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology. 2013. Hagstrom Stephanie A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration. Ophthalmology. 2013. Abedi Farshad, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. Pharmacogenomics. 2013. Jensen Brian C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic influence of LOC387715/HTRA1 on the efficacy of bevacizumab treatment for age-related macular degeneration in a Korean population. Korean journal of ophthalmology : KJO. 2012. Kang Haeng Ku, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population. Molecular vision. 2013. Chang Woohyok, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. The oncologist. 2013. Bhatta Sumita S, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. Ophthalmology. 2012. Smailhodzic Dzenita, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. Pharmacogenomics. 2012. Agosta Elisa, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population. Pharmacogenomics. 2012. Tian Jun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab. Pharmacogenetics and genomics. 2012. Budai Barna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. The pharmacogenomics journal. 2012. Pohl A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. The pharmacogenomics journal. 2011. Koutras A K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Novel chemosensitive single-nucleotide polymorphism markers to targeted regimens in metastatic colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. Kim Jin C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. European journal of cancer (Oxford, England : 1990). 2011. Cohen E E W, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011. Argiris Athanassios, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer. The pharmacogenomics journal. 2011. Hansen T F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic contribution to drug response. Cancer journal (Sudbury, Mass.). 2011. Watson Roshawn G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SLC19A1 pharmacogenomics summary. Pharmacogenetics and genomics. 2010. Yee Sook Wah, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. Anti-cancer drugs. 2010. Chen Jen-Shi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Vascular endothelial growth factor pathway. Pharmacogenetics and genomics. 2010. Maitland Michael L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. Adjei Alex A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evolving novel anti-HER2 strategies. The lancet oncology. 2009. Jones Kellie L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics. Transactions of the American Clinical and Climatological Association. 2010. Goldberg Richard M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers. Gastrointestinal cancer research : GCR. 2009. Yalçin Suayib. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. Pharmacogenomics. 2009. Coltelli Luigi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics and biomarkers in colorectal cancer. The pharmacogenomics journal. 2009. Strimpakos A S, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009. Smit Egbert F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008. Schultheis Anne M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
VEGF inhibition and renal thrombotic microangiopathy. The New England journal of medicine. 2008. Eremina Vera, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of EGFR and VEGF inhibition. Drug discovery today. 2007. Pander Jan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The role of trastuzumab in early stage breast cancer: current data and treatment recommendations. Current treatment options in oncology. 2007. Lin Amy, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. The New England journal of medicine. 2003. Yang James C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer research. 1997. Presta L G, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
50242-060-01
DrugBank:
DB00112
Drugs Product Database (DPD):
2270994
Therapeutic Targets Database:
DAP000393
FDA Drug Label at DailyMed:
939b5d1f-9fb2-4499-80ef-0607aa6b114e

Clinical Trials

These are trials that mention bevacizumab and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.